Neurology
Our Specialists
 Cognitive and Behavioral Neurology
Irene
Hegeman Richard, M.D.
Current Titles and Roles
Associate Professor of Neurology and Psychiatry
Degrees, Certifications, and Licenses
- B.S. with honors and distinction, Cornell University, 1987
- M.D., Yale University School of Medicine, 1991
- Internship, University of Rochester School of Medicine and
Dentistry, 1992
- Residency, University of Rochester School of Medicine and
Dentistry, Neurology, 1995
- Fellowship, University of Rochester School of Medicine
and Dentistry, Movement Disorders and Experimental Therapeutics,
1997
- Certification, American Board of Psychiatry and Neurology
(Neurology), 1996
Prior Work History
2004 - Present, Associate Professor of Neurology and Psychiatry,
University of Rochester School of Medicine and Dentistry,
Rochester, NY
1998 -2004, Assistant Professor of Neurology and
Psychiatry, University of Rochester
School of Medicine and Dentistry, Rochester, New York
1997-1998,
Senior Instructor in Neurology, University of Rochester School
of Medicine and Dentistry, Rochester, New
York
Clinical Specialties
Movement Disorders, Parkinson's disease, Tourette's syndrome
Highlights
Professional Memberships and Working Groups:
- 2001, NIH Working Group to determine research
priorities in the area of cognitive and emotional disturbances
in PD (invited member)
- 2003, NIH Working Group “Depression in Parkinson’s
Disease: Diagnostic Issues” (invited speaker and member)
- 1997-Present, American Academy of Neurology, member
- 1994-1997, American Academy of Neurology, junior member
- 1995- Present, American Neuropsychiatric Association, member
- 1995- Present, Movement Disorder Society, member
- 1988-1989, President, Yale Student Psychiatry
Society, New Haven, CT
Abstracts, Posters and Platform Presentations:
- Frank S, Richard IH, LaDonna K, McDermott M, Justus A, Kurlan
R. Mood Fluctuations During Continuous Levodopa Infusion
in Six Patients with Parkinson’s Disease. Poster Presentation
at the 15th Annual Meeting of the American Neuropsychiatric
Association (ANPA). Bal Harbor, Florida, February 2004.
- LaDonna K, Hartman RL, Richard IH, Podgorsky C. Communicating
for the Public Good: Breaking Myths about Depression and
Parkinson’s
Disease, Presented at the Eastern Communications Association
Conference, Washington, DC, April, 2003.
- Fahn S, Parkinson Study Group (Site Investigator). Evaluation
of the long-duration benefit from levodopa: Results from
the ELLDOPA (Earlier vs. Later LevoDOPA) Study. Movement
Disorders
2003:18(9): 1085-1086.
- Parkinson Study Group (Site Investigator). Does levodopa
slow or hasten the rate of progression of Parkinson disease?
The results
of the ELLDOPA trial. Neurology 2003; 60: A80-81.
- Marek KL, Seibyl J, Parkinson Study Group (Site Investigator).
b-CIT scans without evidence of dopaminergic deficit (SWEDD)
in the ELLDOPA-CIT and CALM-CIT study: Long-term imaging.
Neurology 2003;l60:A293.
- Richard IH, Justus AW, Caine E, Kurlan R. Depressive Symptoms
in Parkinson’s Disease are Underrecognized. Journal
of Neuropsychiatry and Clinical Neurosciences 2002;14:108.
- Parkinson Study Group (Site Investigator). Results of the
ELLDOPA (earlier vs. later levodopa) study. Movement Disorders
2002;
17:Suppl 5, S13.
- Richard, IH; Justus, AW; Greig, N; Marshall, F and Kurlan,
R: Rivastigmine-induced worsening of motor function and mood
in
a patient with Parkinson’s disease. Movement Disorders
2001;16 (supplement 1):S32.
Lectures:
- May, 2004, Neurology Grand Rounds, University of Rochester
Medical Center, “Behind
the Mask: A Look at Depression in Parkinson’s Disease”
- April, 2002, American Academy of Neurology
Annual Meeting (Denver), “Issues
Surrounding the Diagnosis and Treatment of Depression in
Parkinson’s
Disease”
- May, 2001, American Academy of Neurology Annual Meeting
(Philadelphia),
“Parkinson’s Disease: How to Interpret all of the New Clinical Research
Findings”
Funded Research:
- 7/04 - 6/08, (NIH/NINDS) RO1 #NS046487
“
Study of Antidepressants in Parkinson’s Disease (SAD-PD), I. Richard
(PI), total costs ($3,960,094), 25% effort.
- 7/03 - 6/04, (Rosalyn Newman Foundation, Wyeth Pharmaceuticals,
and Novartis Pharmaceuticals), “Double-blind randomized
clinical trial of estrogen replacement therapy in postmenopausal
women with Parkinson’s disease (POETRY)”, L.
Shulman (PI), I. Richard (Site Investigator)
- 4/02-3/04, (NIH/NINDS) Planning Grant R21 #NS43183: Project
Title: Serotonergic Antidepressant in Parkinson’s
Disease (SAD-PD), I. Richard (PI), total costs $225,186,
15% effort.
- 12/02 – 3/05, (Guilford Pharmaceuticals), "A
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group, 2-year Study to Evaluate the Effects
of GPI 1485
on B-CIT/SPECT Scanning and Clinical Efficacy in Symptomatic
Parkinson's Disease Patients Receiving Dopamine Agonist
Therapy",
I. Richard (Site Investigator), total costs $96,600.
- 7/00-6/05, (NIH/NINDS) Mentored Clinical Scientist Patient-Oriented
Research Award K23 #NS02184. “The Relationship
between Mood and Motor Fluctuations in Parkinson’s
Disease”,
I. Richard (PI), total costs $629,667, 75% effort.
Research
- Neuropsychiatry
of movement disorders
Academic Activity
|
